Print selected from 10552348.trn

=>
Uploading C:\Program Files\Stnexp\Queries\10552358-6.str



chain nodes :
10 11 12 13 14 15
ring nodes :
1 2 3 4 5 6 7 8 9
ring/chain nodes :
16 17 18 19 20 21
chain bonds :
10-11 11-12 11-16 11-17 12-13 12-18 12-19 13-14 13-20 13-21 14-15
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
5-7 6-9 7-8 8-9 10-11 13-14 14-15
exact bonds :
11-12 11-16 11-17 12-13 12-18 12-19 13-20 13-21
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:Atom 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS
21:CLASS 22:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Print selected from 10552348.trn

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 12:56:51 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 16478 TO ITERATE

12.1% PROCESSED 2000 ITERATIONS 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 321871 TO 337249
PROJECTED ANSWERS: 1 TO 336

L2 1 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 12:56:57 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 330981 TO ITERATE

99.0% PROCESSED 327586 ITERATIONS 184 ANSWERS

100.0% PROCESSED 330981 ITERATIONS 184 ANSWERS
SEARCH TIME: 00.00.18

L3 184 SEA SSS FUL L1

=> file caplus
FILE 'CAPLUS' ENTERED AT 12:57:19 ON 08 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 8 Sep 2008 VOL 149 ISS 11
FILE LAST UPDATED: 7 Sep 2008 (20080907/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l3
L4 17 L3

Print selected from 10552348.trn

=> d cbib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 17 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
2007:1475771 Document No. 148:100502 Preparation of substituted indoles for treating hepatitis C. Karp, Gary M.; Hwang, Peter Seongwoo; Takasugi, James J.; Ren, Hongyu; Wilde, Richard Gerald; Turpoff, Anthony A.; Arefolov, Alexander; Chen, Guangming; Campbell, Jeffrey A. (USA). U.S. Pat. Appl. Publ. US 20070299068 A1 20071227, 408pp., Cont.-in-part of U.S. Ser. No. 331,180. (English). CODEN: USXXCO. APPLICATION: US 2007-653448 20070116. PRIORITY: US 2006-331180 20060113; US 2006-758527P 20060113.
GI



I



II

AB The title compds. I [X = NO2, CO2H, halo, etc.; Y = (un)substituted benzothiazolyl, indolyl, etc.; Z = alkyl optionally substituted with 5-6 membered heterocyclyl, or 5-6 membered heterocyclyl; R = H; R1 = H, 5-6 membered heterocyclyl, (un)substituted alkyl, etc.; R2 = (un)substituted alkyl, alkylthio, alkyl, etc.; R3 = H; with the provisos], useful for treating Hepatitis C viral infection, were prepared Thus, treating 1-ethyl-6-methoxy-1H,1'H-[2,5']biindolyl-3-carbonitrile with methanesulfonyl chloride afforded 81% II which showed IC50 between 0.5 μM and 2 μM when tested in HCV replicon or HCV-PV systems. This invention provides also pharmaceutical compns. comprising compds. I, and methods of using such compds. or compns. for treating infection by a virus, or for affecting viral IRES activity.
IT 944564-37-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted indoles for treating hepatitis C)
RN 944564-37-8 CAPLUS
CN Carbamic acid, N-[4-[3-cyano-1-ethyl-5-[3-(4-morpholinylamino)propoxy]-1H-indol-2-yl]phenyl]-, cyclopentyl ester (CA INDEX NAME)

Print selected from 10552348.trn



L4 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
2007:911840 Document No. 147:269229 Methods for the selective modulation of PPAR. Shiau, Andrew K.; Massari, Mark Eben; Oshiro, Guy; Kabakibi, Ayman; Malecha, James W.; Noble, Stewart A. (Kalypsys, Inc., USA). U.S. Pat. Appl. Publ. US 20070190079 A1 20070816, 25pp., Cont.-in-part of U.S. Ser. No. 258,463. (English). CODEN: USXXCO. APPLICATION: US 2007-687949 20070319. PRIORITY: US 2004-623252P 20041029; US 2005-258463 20051025; US 2006-783708P 20060317.

AB The present invention relates to methods of selective modulation of peroxisome proliferator activated receptors (PPARs) over G-protein coupled receptor 40 (GPR40), and the use of therapeutically effective amts. of compds. and pharmaceutical compns. which selectively modulate PPAR over GPR40 for the treatment of diseases in patients in need thereof. The methods disclosed herein are exceptionally useful in treating metabolic diseases while avoiding certain side effects common to modulators of PPAR previously disclosed in the art.

IT 781659-23-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(selective modulation of PPAR)

RN 781659-23-2 CAPLUS

CN 1H-Indole-3-acetic acid, 5-[3-[[[2,4-bis(trifluoromethyl)phenyl]methyl](5-ethyl-2-pyrimidinyl)amino]propoxy]- (CA INDEX NAME)



L4 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
2007:817570 Document No. 147:189067 Preparation of substituted indoles for treating hepatitis C. Karp, Gary Mitchell (PTC Therapeutics, Inc., USA). PCT Int. Appl. WO 2007084413 A2 20070726, 701pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK,

LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2007-US923 20070116. PRIORITY: US 2006-758527P 20060113; US 2006-331180 20060113; US 2007-653436 20070113.

GI



I



II

AB The title compds. I [X = CN, NO2, CHO, CO2H, etc.; Y = (un)substituted benzothiazolyl, indolyl, etc.; Z = alkyl optionally substituted with 5-6 membered heterocyclyl, or 5-6 membered heterocyclyl; R = H; R1 = H, 5-6 membered heterocyclyl, (un)substituted alkyl, etc.; R2 = (un)substituted alkyl, alkylthio, alkyl, etc.; R3 = H; with the proviso], useful for treating Hepatitis C viral infection, were prepared Thus, treating 1-ethyl-6-methoxy-1H,1'H-[2,5']biindolyl-3-carbonitrile with methanesulfonyl chloride afforded 81% II which showed IC50 between 0.5 μM and 2 μM when tested in HCV replicon or HCV-PV systems. This invention provides also pharmaceutical compns. comprising compds. I, and methods of using such compds. or compns. for treating infection by a virus, or for affecting viral IRES activity.

IT 944564-37-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted indoles for treating hepatitis C)

RN 944564-37-8 CAPLUS

CN Carbamic acid, N-[4-[3-cyano-1-ethyl-5-[3-(4-morpholinylamino)propoxy]-1H-indol-2-yl]phenyl]-, cyclopentyl ester (CA INDEX NAME)

Print selected from 10552348.trn



L4 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
2006:693649 Document No. 145:305620 Novel potent and selective αvβ3/αvβ5 integrin dual antagonists with reduced binding affinity for human serum albumin. Raboisson, Pierre; Manthey, Carl L.; Chaikin, Margery; Lattanze, Jennifer; Crysler, Carl; Leonard, Kristi; Pan, Wenxi; Tomczuk, Bruce E.; Marugan, Juan Jose (Departments of Medicinal Chemistry, Structural Biology and Molecular Design and Informatics, Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., Exton, PA, 19341, USA). European Journal of Medicinal Chemistry, 41(7), 847-861 (English) 2006. CODEN: EJMCA5. ISSN: 0223-5234. OTHER SOURCES: CASREACT 145:305620. Publisher: Elsevier B.V..
GI



I

AB Pyridopyridineethoxy- and pyridopyridinepropyl-substituted indolepropanoic acids, a pyridineaminopropoxydihydroindoleacetic acid, and a substituted oxopyrrolopyrimidinepropanoic acid are prepared as potential selective dual αvβ3 and αvβ5 integrin receptor antagonists with decreased binding to human serum albumin (HSA). Ammonium tetrahydronaphthyridinylethoxyindolepropanoate I•NH3 is the most effective of the compds. prepared, with subnanomolar affinity for both αvβ3 and αvβ5 (IC50 = 0.29 and 0.16 nM, resp.), low HSA protein binding (40% bound, Kd = 1.1 ± 0.4 + 103 μM), and improved in vitro stability toward human and mouse microsomes (99.9% and 98.7% remaining after 10 min) over previously prepared integrin receptor antagonists. The selectivities of I•NH3 toward α5β1 and IIbIIIa integrins is comparable to those of the initial lead integrin receptor antagonists.

IT 445490-32-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heteroarylalkoxy-substituted indolepropanoic acids and

Print selected from 10552348.trn

analogs as selective dual αvβ3 and αvβ5 integrin receptor antagonists with reduced binding to human serum albumin)

RN 445490-32-4 CAPLUS

CN 1H-Indole-1-propanoic acid, 5-[3-(2-pyridinylamino)propoxy]-, ethyl ester (CA INDEX NAME)



L4 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

2005:497501 Document No. 143:43770 A preparation of indole derivatives, useful for the treatment of PPAR-related diseases. Hsieh, Hsing-Pang; Mahindroo, Neeraj; Hsu, Tsu-An; Huang, Chien-Fu; Chen, Xin; Chao, Yu-Sheng (Taiwan). U.S. Pat. Appl. Publ. US 20050124675 A1 20050609, 61 pp. (English). CODEN: USXXCO. APPLICATION: US 2004-3181 20041203. PRIORITY: US 2003-526872P 20031204.

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a preparation of indole derivs., useful for the treatment of PPAR-related diseases. For instance, indole derivative I was prepared via etherification of 7-propyl-3-trifluoromethyl-benzo[d]isoxazol-6-ol by (chloropropyl)indole derivative II and subsequent hydrolysis (yields: etherification - 85%, hydrolysis - 90%). In PPARα transactivation assay 43 compds. showed EC50 values lower than 1 μM.

IT 853652-09-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indole derivs. useful for the treatment of PPAR-related diseases)

RN 853652-09-2 CAPLUS

CN 1H-Indole-1-acetic acid, 4-[3-(methyl-2-pyridinylamino)propoxy]- (CA INDEX NAME)

Print selected from 10552348.trn



L4 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
2005:378911 Document No. 143:78032 Non-peptidic αvβ3 antagonists containing indol-1-ylpropionic acids. Leonard, Kristi; Pan, Wenxi; Anaclerio, Beth; Gushue, Joan M.; Guo, Zihong; DesJarlais, Renee L.; Chaikin, Marge A.; Lattanze, Jennifer; Crysler, Carl; Manthey, Carl L.; Tomczuk, Bruce E.; Marugan, Juan Jose (Pharmaceutical Research and Development, L.L.C., Johnson & Johnson, Exton, PA, 19341, USA). Bioorganic & Medicinal Chemistry Letters, 15(10), 2679-2684 (English) 2005. CODEN: BMCLE8. ISSN: 0960-894X. OTHER SOURCES: CASREACT 143:78032. Publisher: Elsevier B.V..
AB The synthesis and structure/activity relationship of RGD mimetics that are potent inhibitors of the integrin αvβ3 are described. Indol-1-ylpropionic acids containing a variety of basic moieties at the 5-position, as well as substitutions alpha and beta to the carboxy terminus were synthesized and evaluated. Novel compds. with improved potency have been identified.
IT 445489-78-1P 445489-79-2P 445489-80-5P
445490-29-9P 855313-65-4P 855313-66-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of indol-1-ylpropionic acids as non-peptidic vitronectin αvβ3 receptor antagonists)
RN 445489-78-1 CAPLUS
CN 1H-Indole-1-propanoic acid, α-(phenylmethyl)-5-[3-(2-pyridinylamino)propoxy]- (CA INDEX NAME)



RN 445489-79-2 CAPLUS
CN 1H-Indole-1-propanoic acid, α-methyl-5-[3-(2-pyridinylamino)propoxy]- (CA INDEX NAME)

Print selected from 10552348.trn



RN 445489-80-5 CAPLUS
CN 1H-Indole-1-propanoic acid, α-propyl-5-[3-(2-pyridinylamino)propoxy]- (CA INDEX NAME)



RN 445490-29-9 CAPLUS
CN 1H-Indole-1-propanoic acid, 5-[3-(2-pyridinylamino)propoxy]- (CA INDEX NAME)



RN 855313-65-4 CAPLUS
CN Benzoic acid, 3-[5-[3-(2-pyridinylamino)propoxy]-1H-indol-1-yl]- (CA INDEX NAME)



RN 855313-66-5 CAPLUS
CN Benzoic acid, 4-[5-[3-(2-pyridinylamino)propoxy]-1H-indol-1-yl]- (CA INDEX NAME)

Print selected from 10552348.trn



IT 445490-32-4P 855313-63-2P 855313-64-3P
855313-73-4P 855313-74-5P 855313-75-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indol-1-ylpropionic acids as non-peptidic vitronectin αvβ3 receptor antagonists)

RN 445490-32-4 CAPLUS
CN 1H-Indole-1-propanoic acid, 5-[3-(2-pyridinylamino)propoxy]-, ethyl ester (CA INDEX NAME)



RN 855313-63-2 CAPLUS
CN Benzoic acid, 3-[5-[3-(2-pyridinylamino)propoxy]-1H-indol-1-yl]-, ethyl ester (CA INDEX NAME)



RN 855313-64-3 CAPLUS
CN Benzoic acid, 4-[5-[3-(2-pyridinylamino)propoxy]-1H-indol-1-yl]-, ethyl ester (CA INDEX NAME)



RN 855313-73-4 CAPLUS
CN 1H-Indole-1-propanoic acid, α-methyl-5-[3-(2-pyridinylamino)propoxy]-

Print selected from 10552348.trn

, ethyl ester (CA INDEX NAME)



RN 855313-74-5 CAPLUS
CN 1H-Indole-1-propanoic acid, α-propyl-5-[3-(2-pyridinylamino)propoxy]-, ethyl ester (CA INDEX NAME)



RN 855313-75-6 CAPLUS
CN 1H-Indole-1-propanoic acid, α-(phenylmethyl)-5-[3-(2-pyridinylamino)propoxy]-, ethyl ester (CA INDEX NAME)



L4 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
2005:80539 Document No. 142:336209 Design, Synthesis, and Biological Evaluation of Novel Potent and Selective αvβ3/αvβ5 Integrin Dual Inhibitors with Improved Bioavailability. Selection of the Molecular Core. Marugan, Juan Jose; Manthey, Carl; Anaclerio, Beth; Lafrance, Lou; Lu, Tianbao; Markotan, Tom; Leonard, Kristi A.; Crysler, Carl; Eisennagel, Stephen; Dasgupta, Malini; Tomczuk, Bruce (Johnson and Johnson Pharmaceutical Research and Development, LLC, Exton, IA, 19341, USA). Journal of Medicinal Chemistry, 48(4), 926-934 (English) 2005. CODEN: JMCMAR. ISSN: 0022-2623. OTHER SOURCES: CASREACT 142:336209. Publisher: American Chemical Society.
GI

Print selected from 10552348.trn



I



II



III

AB A novel series of potent and selective αvβ3/αvβ5 dual inhibitors was designed, synthesized, and evaluated against several integrins. These compds. were synthesized through a Mitsunobu reaction between the guanidinium mimetics and the corresponding central templates. Guanidinium mimetics with enhanced rigidity [i.e., [(2-pyridinyl)amino]propoxy vs. the 2-(6-methylamino-2-pyridinyl)ethoxy] led to improved activity toward αvβ3. Exemplary oral bioavailability in mice was achieved using the indole central scaffold. Although, oral bioavailability was maintained when the indole mol. core was replaced with the bioisosteric benzofuran or benzothiophene ring systems, it was found to not significantly impact the integrin activity or selectivity. However, the indole series displayed the best in vivo pharmacokinetic properties. Thus, the indole series was selected for further structure-activity relationships to obtain more potent αvβ3/αvβ5 dual antagonist with improved oral bioavailability. The compds. thus prepared and studied included 5-[3-(2-pyridinylamino)propoxy]-1H-indole-1-propanoic acid (I), 5-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-1H-indole-1-propanoic acid, 6-[2-[6-(methylamino)-2-pyridinyl]ethoxy]benzo[b]thiophene-3-propanoic acid (II), and 6-[2-[6-(methylamino)-2-pyridinyl]ethoxy]-3-benzofuranpropanoic acid (III).

IT 445490-29-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of [[[(pyridinyl)amino]propoxy]-1H-indole-1-propanoic acid (guanidinium mimetic) and study of its activity as dual αvβ3/αvβ5 integrin inhibitor)

RN 445490-29-9 CAPLUS

CN 1H-Indole-1-propanoic acid, 5-[3-(2-pyridinylamino)propoxy]- (CA INDEX NAME)



Print selected from 10552348.trn

IT 445490-32-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of [[[(pyridinyl)amino]propoxy]-1H-indole-1-propanoic acid using ester as synthetic intermediate)
RN 445490-32-4 CAPLUS
CN 1H-Indole-1-propanoic acid, 5-[3-(2-pyridinylamino)propoxy]-, ethyl ester (CA INDEX NAME)



L4 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
2004:995905 Document No. 142:6415 Preparation of indoleacetic acids for the treatment of diabetes and related diseases.. Ma, Xin; Cantin, Louis-David; Choi, Soongyu; Clark, Roger; Hentemann, Martin; Rudolph, Joachim; Lavoie, Rico; Zhang, Zhonghua (Bayer Pharmaceuticals Corporation, USA). PCT Int. Appl. WO 2004098498 A2 20041118, 142 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2004-US12959 20040428. PRIORITY: US 2003-466143P 20030428.
GI



I

AB Title compds. [I; R1 = H, alkyl, PhCH2; R2, R3 = H, alkyl; Y = O, NR5; R5 = H, alkyl, cycloalkylalkyl; n = 2-4; Ar = (substituted) Ph, heteroaryl], were prepared for the treatment of diseases such as diabetes and metabolic syndrome X (no data). Thus, 1-(2-bromoethoxy)-4-ethyl-2-methoxybenzene (preparation given), Me 2-(5-hydroxyindol-1-yl)propionate (preparation given) and

Cs2CO3 were heated at 140° in DMF for 3 h followed by addition of HCl to pH 2 to give 8% 2-[5-[2-(4-ethyl-2-methoxyphenoxy)ethoxy]indol-1-yl]propionic acid.

IT 796100-26-0P 796100-34-0P 796100-36-2P
796102-24-4P 796102-26-6P 796102-29-9P
796102-31-3P 796102-34-6P 796102-36-8P
796102-38-0P 796102-40-4P 796102-42-6P
796102-44-8P 796102-46-0P 796102-48-2P
796102-50-6P 796102-52-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indoleacetic acids for the treatment of diabetes and related diseases)

RN 796100-26-0 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[3-[[5-fluoro-2-(4-methoxyphenyl)-4-pyrimidinyl]methylamino]propoxy]- (CA INDEX NAME)



RN 796100-34-0 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[3-[[2-(4-fluorophenyl)-5-methyl-4-pyrimidinyl]methylamino]propoxy]- (CA INDEX NAME)



RN 796100-36-2 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[3-[(2-chloro-5-fluoro-4-pyrimidinyl)methylamino]propoxy]-α-methyl-, methyl ester (CA INDEX NAME)



Print selected from 10552348.trn

RN 796102-24-4 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[3-[[2-(4-ethylphenyl)-5-methyl-4-pyrimidinyl]methylamino]propoxy]- (CA INDEX NAME)



RN 796102-26-6 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[3-[[2-(1,3-benzodioxol-5-yl)-5-methyl-4-pyrimidinyl]methylamino]propoxy]- (CA INDEX NAME)



RN 796102-29-9 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[3-[[2-(1,3-benzodioxol-5-yl)-4-pyrimidinyl]methylamino]propoxy]-α-methyl- (CA INDEX NAME)



RN 796102-31-3 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[3-[[2-(4-ethylphenyl)-5-fluoro-4-pyrimidinyl]methylamino]propoxy]- (CA INDEX NAME)



Print selected from 10552348.trn

RN 796102-34-6 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[3-[[2-(1,3-benzodioxol-5-yl)-5-fluoro-4-pyrimidinyl]methylamino]propoxy]- (CA INDEX NAME)



RN 796102-36-8 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[3-[[5-fluoro-2-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]methylamino]propoxy]- (CA INDEX NAME)



RN 796102-38-0 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[3-[(2-chloro-5-fluoro-4-pyrimidinyl)methylamino]propoxy]- (CA INDEX NAME)



RN 796102-40-4 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[3-[[5-fluoro-2-[4-(trifluoromethoxy)phenyl]-4-pyrimidinyl]methylamino]propoxy]- (CA INDEX NAME)



RN 796102-42-6 CAPLUS

Print selected from 10552348.trn

CN 1H-Indole-1-acetic acid, 5-[3-[[2-(4-ethylphenyl)-5-fluoro-4-pyrimidinyl]amino]propoxy]-α-methyl- (CA INDEX NAME)



RN 796102-44-8 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[3-[[5-fluoro-2-(4-methoxyphenyl)-4-pyrimidinyl]amino]propoxy]-α-methyl- (CA INDEX NAME)



RN 796102-46-0 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[3-[[5-fluoro-2-(4-fluorophenyl)-4-pyrimidinyl]amino]propoxy]-α-methyl- (CA INDEX NAME)



RN 796102-48-2 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[3-[[2-(4-ethylphenyl)-5-fluoro-4-pyrimidinyl]methylamino]propoxy]-α-methyl- (CA INDEX NAME)



Print selected from 10552348.trn

RN 796102-50-6 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[3-[[5-fluoro-2-(4-methoxyphenyl)-4-pyrimidinyl]methylamino]propoxy]-α-methyl- (CA INDEX NAME)



RN 796102-52-8 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[3-[[5-fluoro-2-(4-fluorophenyl)-4-pyrimidinyl]methylamino]propoxy]-α-methyl- (CA INDEX NAME)



IT 796100-20-4P 796100-22-6P 796100-24-8P
796100-28-2P 796100-30-6P 796100-32-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indoleacetic acids for the treatment of diabetes and related diseases)
RN 796100-20-4 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[3-[(2-chloro-5-fluoro-4-pyrimidinyl)methylamino]propoxy]-, methyl ester (CA INDEX NAME)



RN 796100-22-6 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[3-[(2-chloro-5-fluoro-4-pyrimidinyl)amino]propoxy]-α-methyl-, methyl ester (CA INDEX NAME)

Print selected from 10552348.trn



RN 796100-24-8 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[3-[[5-fluoro-2-(4-methoxyphenyl)-4-pyrimidinyl]methylamino]propoxy]-, methyl ester (CA INDEX NAME)



RN 796100-28-2 CAPLUS
CN 4-Pyrimidinamine, 2-chloro-N-[3-(1H-indol-5-yloxy)propyl]-N,5-dimethyl- (CA INDEX NAME)



RN 796100-30-6 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[3-[(2-chloro-5-methyl-4-pyrimidinyl)methylamino]propoxy]-, ethyl ester (CA INDEX NAME)



Print selected from 10552348.trn

RN 796100-32-8 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[3-[[2-(4-fluorophenyl)-5-methyl-4-pyrimidinyl]methylamino]propoxy]-, ethyl ester (CA INDEX NAME)



L4 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
2004:902348 Document No. 141:379812 Preparation of N-containing heteroaromatic compounds as modulators of PPARs and methods of treating metabolic disorders. Liu, Kevin; Zhao, Cunxiang (Kalypsys, Inc., USA). PCT Int. Appl. WO 2004092130 A2 20041028, 124 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2004-US10737 20040407. PRIORITY: US 2003-461574P 20030407; US 2003-461606P 20030407; US 2003-461586P 20030407.
GI



I



II

AB Heteroarom. compds. of formula I [Ar = mono- or bicyclic aromatic ring with at least one N; L = bond, CH2; R1, R2 = alkyl, heteroaryl, etc.; R3, R4 = H, alkyl, heteroaryl, etc.; n = 1-3] are prepared as modulators of peroxisome proliferator activated receptors (PPAR). Pharmaceutical

compns. comprising I, and methods of treating disease using I are disclosed. Thus, II was prepared and had EC50 < 1 μM against human PPARγ.

IT 781659-23-2P 781659-24-3P 781659-25-4P
781659-26-5P 781659-27-6P 781659-28-7P
781659-29-8P 781659-30-1P 781659-31-2P
781659-43-6P 781659-44-7P 781659-45-8P
781659-46-9P 781659-47-0P 781659-48-1P
781659-49-2P 781659-50-5P 781659-51-6P
781659-52-7P 781659-53-8P 781659-54-9P
781659-55-0P 781659-56-1P 781659-57-2P
781659-58-3P 781659-59-4P 781659-60-7P
781659-61-8P 781659-62-9P 781659-63-0P
781659-64-1P 781659-65-2P 781659-66-3P
781659-67-4P 781659-68-5P 781659-69-6P
781659-70-9P 781659-71-0P 781659-72-1P
781659-73-2P 781659-74-3P 781659-75-4P
781659-76-5P 781659-77-6P 781659-78-7P
781659-79-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-containing heteroarom. compds. as modulators of PPARs for treating metabolic disorders)

RN 781659-23-2 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[[[2,4-bis(trifluoromethyl)phenyl]methyl](5-ethyl-2-pyrimidinyl)amino]propoxy]- (CA INDEX NAME)



RN 781659-24-3 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[[[2,4-bis(trifluoromethyl)phenyl]methyl](5-ethyl-2-pyrimidinyl)amino]propoxy]-1-methyl- (CA INDEX NAME)



Print selected from 10552348.trn

RN 781659-25-4 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[butyl(5-ethyl-2-pyrimidinyl)amino]propoxy]- (CA INDEX NAME)



RN 781659-26-5 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-(butyl-2-pyridinylamino)propoxy]- (CA INDEX NAME)



RN 781659-27-6 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-(2-benzothiazolylbutylamino)propoxy]- (CA INDEX NAME)



RN 781659-28-7 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-(2-benzoxazolylbutylamino)propoxy]- (CA INDEX NAME)



RN 781659-29-8 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[2-benzoxazolyl[[2,4-bis(trifluoromethyl)phenyl]methyl]amino]propoxy]- (CA INDEX NAME)

Print selected from 10552348.trn



RN 781659-30-1 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[[[2,4-bis(trifluoromethyl)phenyl]methyl]-2-pyridinylamino]propoxy]- (CA INDEX NAME)



RN 781659-31-2 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[2-benzothiazolyl[[2,4-bis(trifluoromethyl)phenyl]methyl]amino]propoxy]- (CA INDEX NAME)



RN 781659-43-6 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[methyl(5-methyl-2-pyrimidinyl)amino]propoxy]- (CA INDEX NAME)

Print selected from 10552348.trn



RN 781659-44-7 CAPLUS
CN 1H-Indole-3-acetic acid, 1-methyl-5-[3-[methyl(5-methyl-2-pyrimidinyl)amino]propoxy]- (CA INDEX NAME)



RN 781659-45-8 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[ethyl(5-methyl-2-pyrimidinyl)amino]propoxy]- (CA INDEX NAME)



RN 781659-46-9 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[ethyl(5-methyl-2-pyrimidinyl)amino]propoxy]-1-methyl- (CA INDEX NAME)



RN 781659-47-0 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[(5-ethyl-2-pyrimidinyl)methylamino]propoxy]- (CA INDEX NAME)

Print selected from 10552348.trn



RN 781659-48-1 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[(5-ethyl-2-pyrimidinyl)methylamino]propoxy]-1-methyl- (CA INDEX NAME)



RN 781659-49-2 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[ethyl(5-ethyl-2-pyrimidinyl)amino]propoxy]- (CA INDEX NAME)



RN 781659-50-5 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[ethyl(5-ethyl-2-pyrimidinyl)amino]propoxy]-1-methyl- (CA INDEX NAME)



RN 781659-51-6 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[(5-methyl-2-pyrimidinyl)(phenylmethyl)amino]propoxy]- (CA INDEX NAME)

Print selected from 10552348.trn



RN 781659-52-7 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[(5-ethyl-2-pyrimidinyl)(phenylmethyl)amino]propoxy]- (CA INDEX NAME)



RN 781659-53-8 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[[(2-methylphenyl)methyl](5-methyl-2-pyrimidinyl)amino]propoxy]- (CA INDEX NAME)



RN 781659-54-9 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[(5-ethyl-2-pyrimidinyl)[(2-methylphenyl)methyl]amino]propoxy]- (CA INDEX NAME)



Print selected from 10552348.trn

RN 781659-55-0 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[[(4-methylphenyl)methyl](5-methyl-2-pyrimidinyl)amino]propoxy]- (CA INDEX NAME)



RN 781659-56-1 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[(5-ethyl-2-pyrimidinyl)[(4-methylphenyl)methyl]amino]propoxy]- (CA INDEX NAME)



RN 781659-57-2 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[[(2,4-dimethylphenyl)methyl](5-methyl-2-pyrimidinyl)amino]propoxy]- (CA INDEX NAME)



RN 781659-58-3 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[(5-ethyl-2-pyrimidinyl)[(4-methoxyphenyl)methyl]amino]propoxy]- (CA INDEX NAME)

Print selected from 10552348.trn



RN 781659-59-4 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[(5-methyl-2-pyrimidinyl)[[4-(trifluoromethyl)phenyl]methyl]amino]propoxy]- (CA INDEX NAME)



RN 781659-60-7 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[(5-ethyl-2-pyrimidinyl)[[4-(trifluoromethyl)phenyl]methyl]amino]propoxy]- (CA INDEX NAME)



RN 781659-61-8 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[(5-methyl-2-pyrimidinyl)[[2-(trifluoromethyl)phenyl]methyl]amino]propoxy]- (CA INDEX NAME)

Print selected from 10552348.trn



RN 781659-62-9 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[(5-ethyl-2-pyrimidinyl)[[2-(trifluoromethyl)phenyl]methyl]amino]propoxy]- (CA INDEX NAME)



RN 781659-63-0 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[[[2,4-bis(trifluoromethyl)phenyl]methyl](5-methyl-2-pyrimidinyl)amino]propoxy]- (CA INDEX NAME)



RN 781659-64-1 CAPLUS
CN 1H-Indole-3-acetic acid, 1-methyl-5-[3-[(5-methyl-2-pyrimidinyl)(phenylmethyl)amino]propoxy]- (CA INDEX NAME)

Print selected from 10552348.trn



RN 781659-65-2 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[(5-ethyl-2-pyrimidinyl)(phenylmethyl)amino]propoxy]-1-methyl- (CA INDEX NAME)



RN 781659-66-3 CAPLUS
CN 1H-Indole-3-acetic acid, 1-methyl-5-[3-[[(4-methylphenyl)methyl](5-methyl-2-pyrimidinyl)amino]propoxy]- (CA INDEX NAME)



RN 781659-67-4 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[(5-ethyl-2-pyrimidinyl)[(4-methylphenyl)methyl]amino]propoxy]-1-methyl- (CA INDEX NAME)



Print selected from 10552348.trn

RN 781659-68-5 CAPLUS
CN 1H-Indole-3-acetic acid, 1-methyl-5-[3-[[(2-methylphenyl)methyl](5-methyl-2-pyrimidinyl)amino]propoxy]- (CA INDEX NAME)



RN 781659-69-6 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[(5-ethyl-2-pyrimidinyl)[(3-methylphenyl)methyl]amino]propoxy]-1-methyl- (CA INDEX NAME)



RN 781659-70-9 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[[(2,4-dimethylphenyl)methyl](5-methyl-2-pyrimidinyl)amino]propoxy]-1-methyl- (CA INDEX NAME)



RN 781659-71-0 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[[(2,4-dimethylphenyl)methyl](5-ethyl-2-pyrimidinyl)amino]propoxy]-1-methyl- (CA INDEX NAME)

Print selected from 10552348.trn



RN 781659-72-1 CAPLUS
CN 1H-Indole-3-acetic acid, 1-methyl-5-[3-[(5-methyl-2-pyrimidinyl)[[4-(trifluoromethyl)phenyl]methyl]amino]propoxy]- (CA INDEX NAME)



RN 781659-73-2 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[(5-ethyl-2-pyrimidinyl)[[4-(trifluoromethyl)phenyl]methyl]amino]propoxy]-1-methyl- (CA INDEX NAME)



RN 781659-74-3 CAPLUS
CN 1H-Indole-3-acetic acid, 1-methyl-5-[3-[(5-methyl-2-pyrimidinyl)[[2-(trifluoromethyl)phenyl]methyl]amino]propoxy]- (CA INDEX NAME)

Print selected from 10552348.trn



RN 781659-75-4 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[(5-ethyl-2-pyrimidinyl)[[2-(trifluoromethyl)phenyl]methyl]amino]propoxy]-1-methyl- (CA INDEX NAME)



RN 781659-76-5 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[[[2,4-bis(trifluoromethyl)phenyl]methyl](5-methyl-2-pyrimidinyl)amino]propoxy]-1-methyl- (CA INDEX NAME)



RN 781659-77-6 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[[[2,4-bis(trifluoromethyl)phenyl]methyl](5-ethyl-2-pyrimidinyl)amino]propoxy]-1-methyl-, methyl ester (CA INDEX NAME)

Print selected from 10552348.trn



RN 781659-78-7 CAPLUS
CN 1H-Indole-3-acetic acid, 5-[3-[[[2,4-bis(trifluoromethyl)phenyl]methyl](5-ethyl-2-pyrimidinyl)amino]propoxy]-, methyl ester (CA INDEX NAME)



RN 781659-79-8 CAPLUS
CN 1H-Indole-3-acetic acid, 1-acetyl-5-[3-[(5-methyl-2-pyrimidinyl)[[2-(trifluoromethyl)phenyl]methyl]amino]propoxy]- (CA INDEX NAME)



L4 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
2004:569863 Document No. 141:123559 A preparation of indole derivatives, useful as integrin inhibitors. Wiesner, Matthias; Goodman, Simon; Gottschlich, Rudolf (Germany). U.S. Pat. Appl. Publ. US 20040138284 A1 20040715, 33 pp., Cont.-in-part of U.S. Ser. No. 203,406. (English).

Print selected from 10552348.trn

CODEN: USXXCO. APPLICATION: US 2004-750879 20040105. PRIORITY: DE 2000-10006139 20000211; WO 2001-EP84 20010105; US 2002-203406 20020809.

GI



I

AB The invention relates to a preparation of indole derivs. of formula I [wherein: A and B are independently selected from O, S, NH, NH, C(O), or C(O)NH, etc.; X is (un)substituted alkylene; R1 is H, C1-6alkyl, or (CH2)0-2-aryl; R2 is H, (cyclo)alkyl, or -C(O)-alkyl; R3 is NH2, -NHC(O)-alkyl, -NH(CO)-aryl, etc.; R4 and R5 are independently selected from H, oxo, (cyclo)alkyl, C(O)NH2, or NH-heterocycle, etc.], useful as integrin inhibitors (no biol. data). Compds. of formula I can be employed for combating thromboses, cardiac infarction, coronary heart diseases, arteriosclerosis, inflammations, tumors, osteoporosis, rheumatic arthritis, macular degenerative disease, and diabetic retinopathy, etc. The invention compds. act as integrin inhibitors, inhibiting, in particular, the interaction of the αv-, β3- and β5-integrin receptors with ligands (no biol. data).

IT 354822-33-6P 354822-40-5P 354822-49-4P
354822-62-1P 354822-69-8P 354822-83-6P
354822-85-8P 354822-86-9P 354822-88-1P
354822-89-2P 354822-90-5P 354822-93-8P
354822-95-0P 354822-97-2P 354823-01-1P
354823-03-3P 354823-06-6P 354823-18-0P
354823-25-9P 354823-28-2P 354823-43-1P
354823-47-5P 354823-49-7P 354823-52-2P
354823-55-5P 724478-49-3P 724478-55-1P
724478-56-2P 724478-60-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indole derivs., useful as integrin inhibitors)

RN 354822-33-6 CAPLUS

CN 1H-Indole-3-propanoic acid, β-phenyl-6-[3-(2-pyridinylamino)propoxy]- (CA INDEX NAME)



Print selected from 10552348.trn

RN 354822-40-5 CAPLUS
CN 1H-Indole-3-propanoic acid, 6-[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]propoxy]-β-phenyl- (CA INDEX NAME)



RN 354822-49-4 CAPLUS
CN 1H-Indole-3-propanoic acid, β-(3-hydroxyphenyl)-6-[3-[(3,4,5,6-tetrahydro-2-pyridinyl)amino]propoxy]- (CA INDEX NAME)



RN 354822-62-1 CAPLUS
CN 1H-Indole-3-propanoic acid, β-(3-chlorophenyl)-6-[3-(2-pyridinylamino)propoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354822-46-1
CMF C25 H24 Cl N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2

Print selected from 10552348.trn



RN 354822-69-8 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-5-[3-(2-pyridinylamino)propoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354822-36-9
CMF C25 H25 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 354822-83-6 CAPLUS
CN 1H-Indole-3-propanoic acid, β-(4-fluorophenyl)-6-[3-(2-pyridinylamino)propoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354822-41-6
CMF C25 H24 F N3 O3



Print selected from 10552348.trn

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 354822-85-8 CAPLUS
CN 1H-Indole-3-propanoic acid, β-[3,5-bis(trifluoromethyl)phenyl]-6-[3-(2-pyridinylamino)propoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354822-84-7
CMF C27 H23 F6 N3 O3





CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 354822-86-9 CAPLUS

Print selected from 10552348.trn

CN 1H-Indole-3-propanoic acid, β-(3,5-dichlorophenyl)-6-[3-(2-pyridinylamino)propoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354822-42-7
CMF C25 H23 Cl2 N3 O3





CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 354822-88-1 CAPLUS
CN 1H-Indole-3-propanoic acid, β-(2,4-dichlorophenyl)-6-[3-(2-pyridinylamino)propoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354822-87-0
CMF C25 H23 Cl2 N3 O3



Print selected from 10552348.trn

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 354822-89-2 CAPLUS
CN 1H-Indole-3-propanoic acid, β-[4-chloro-3-(trifluoromethyl)phenyl]-6-[3-(2-pyridinylamino)propoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354822-43-8
CMF C26 H23 Cl F3 N3 O3





CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 354822-90-5 CAPLUS

Print selected from 10552348.trn

CN 1H-Indole-3-propanoic acid, β-cyclohexyl-6-[3-(2-pyridinylamino)propoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354822-44-9
CMF C25 H31 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 354822-93-8 CAPLUS
CN 1H-Indole-3-propanoic acid, β-(2,6-difluorophenyl)-6-[3-(2-pyridinylamino)propoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354822-92-7
CMF C25 H23 F2 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2

Print selected from 10552348.trn



RN 354822-95-0 CAPLUS
CN 1H-Indole-3-propanoic acid, β-(2-chloro-3,6-difluorophenyl)-6-[3-(2-pyridinylamino)propoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354822-94-9
CMF C25 H22 Cl F2 N3 O3





CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 354822-97-2 CAPLUS
CN 1H-Indole-3-propanoic acid, 6-[3-(2-pyridinylamino)propoxy]-β-(2,4,6-trifluorophenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354822-96-1

Print selected from 10552348.trn

CMF C25 H22 F3 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 354823-01-1 CAPLUS
CN 1H-Indole-3-propanoic acid, 6-[3-(2-pyridinylamino)propoxy]-β-[4-(trifluoromethoxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354823-00-0
CMF C26 H24 F3 N3 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



Print selected from 10552348.trn

RN 354823-03-3 CAPLUS
CN 1H-Indole-3-propanoic acid, 6-[3-(2-pyridinylamino)propoxy]-β-[3-(trifluoromethoxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354823-02-2
CMF C26 H24 F3 N3 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 354823-06-6 CAPLUS
CN 2,1,3-Benzothiadiazole-5-propanoic acid, β-[6-[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]propoxy]-1H-indol-3-yl]- (CA INDEX NAME)



RN 354823-18-0 CAPLUS
CN 1H-Indole-3-propanoic acid, 6-[3-[(4,5-dihydro-5-oxo-1H-imidazol-2-yl)amino]propoxy]-β-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354823-17-9
CMF C23 H24 N4 O4

Print selected from 10552348.trn



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 354823-25-9 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-6-[3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propoxy]- (CA INDEX NAME)



RN 354823-28-2 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-6-[3-[(3,4,5,6-tetrahydro-2-pyridinyl)amino]propoxy]- (CA INDEX NAME)



RN 354823-43-1 CAPLUS

Print selected from 10552348.trn

CN 1H-Indole-3-propanoic acid, 6-[3-[[3-(acetylamino)-2-pyridinyl]amino]propoxy]-β-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354823-42-0
CMF C27 H28 N4 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 354823-47-5 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-6-[3-(2-pyridinylamino)propoxy]-, (βS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 354823-49-7 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-6-[3-(2-pyridinylamino)propoxy]-, hydrochloride (1:1), (βS)- (CA INDEX NAME)

Absolute stereochemistry.

Print selected from 10552348.trn



● HCl

RN 354823-52-2 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-6-[3-(2-pyridinylamino)propoxy]-, (βS)-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 354823-47-5
CMF C25 H25 N3 O3

Absolute stereochemistry.



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 354823-55-5 CAPLUS
CN 1H-Indole-3-propanoic acid, 6-[3-(1H-imidazol-2-ylamino)propoxy]-β-phenyl- (CA INDEX NAME)

Print selected from 10552348.trn



RN 724478-49-3 CAPLUS
CN 1H-Indole-3-propanoic acid, β-4-pyridinyl-6-[3-(2-pyridinylamino)propoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354822-45-0
CMF C24 H24 N4 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 724478-55-1 CAPLUS
CN 2,1,3-Benzothiadiazole-5-propanoic acid, β-[6-[3-(2-pyridinylamino)propoxy]-1H-indol-3-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354822-48-3
CMF C25 H23 N5 O3 S

Print selected from 10552348.trn



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 724478-56-2 CAPLUS
CN 1H-Indole-3-propanoic acid, β-[4-(methoxycarbonyl)phenyl]-6-[3-(2-pyridinylamino)propoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354822-50-7
CMF C27 H27 N3 O5



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 724478-60-8 CAPLUS

Print selected from 10552348.trn

CN 1H-Indole-3-propanoic acid, β-1,5-cyclohexadien-1-yl-6-[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]propoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 724478-59-5
CMF C23 H28 N4 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 354822-36-9 354822-55-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of indole derivs., useful as integrin inhibitors)
RN 354822-36-9 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-5-[3-(2-pyridinylamino)propoxy]- (CA INDEX NAME)



RN 354822-55-2 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-6-[3-[2-pyridinyl[(2,2,2-trichloroethoxy)carbonyl]amino]propoxy]-, ethyl ester (CA INDEX NAME)

Print selected from 10552348.trn



IT 354822-56-3P 354822-58-5P 354822-60-9P
354822-98-3P 354823-04-4P 354823-19-1P
354823-21-5P 354823-23-7P 354823-26-0P
354823-38-4P 724478-51-7P 724478-52-8P
724478-54-0P 724478-57-3P 724478-58-4P
724478-62-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indole derivs., useful as integrin inhibitors)
RN 354822-56-3 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-6-[3-(2-pyridinylamino)propoxy]-, ethyl ester (CA INDEX NAME)



RN 354822-58-5 CAPLUS
CN 1H-Indole-3-propanoic acid, 6-[3-[1H-imidazol-2-yl[(2,2,2-trichloroethoxy)carbonyl]amino]propoxy]-β-phenyl-, ethyl ester (CA INDEX NAME)



RN 354822-60-9 CAPLUS
CN 1H-Indole-3-propanoic acid, 6-[3-(1H-imidazol-2-ylamino)propoxy]-β-

Print selected from 10552348.trn

phenyl-, ethyl ester (CA INDEX NAME)



RN 354822-98-3 CAPLUS
CN 2-Pyridinamine, N-[3-(1H-indol-6-yloxy)propyl]- (CA INDEX NAME)



RN 354823-04-4 CAPLUS
CN 1H-Imidazol-2-amine, 4,5-dihydro-N-[3-(1H-indol-6-yloxy)propyl]- (CA INDEX NAME)



RN 354823-19-1 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-6-[3-(2-pyrimidinylamino)propoxy]-, ethyl ester (CA INDEX NAME)



RN 354823-21-5 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-6-[3-(2-pyrimidinylamino)propoxy]- (CA INDEX NAME)

Print selected from 10552348.trn



RN 354823-23-7 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-6-[3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propoxy]-, ethyl ester (CA INDEX NAME)



RN 354823-26-0 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-6-[3-[(3,4,5,6-tetrahydro-2-pyridinyl)amino]propoxy]-, ethyl ester (CA INDEX NAME)



RN 354823-38-4 CAPLUS
CN 1H-Indole-3-propanoic acid, 6-[3-[(3-nitro-2-pyridinyl)amino]propoxy]-β-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354823-37-3
CMF C25 H24 N4 O5

Print selected from 10552348.trn



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 724478-51-7 CAPLUS
CN Pyridinium, 2-[[3-(1H-indol-6-yloxy)propyl]amino]-1-(phenylmethyl)-, bromide (1:1) (CA INDEX NAME)



● Br^-

RN 724478-52-8 CAPLUS
CN Pyridinium, 2-[[3-[[3-[2-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-yl)-1-(4-fluorophenyl)ethyl]-1H-indol-6-yl]oxy]propyl]amino]-1-(phenylmethyl)-, bromide (1:1) (CA INDEX NAME)

Print selected from 10552348.trn



RN 724478-54-0 CAPLUS
CN Pyridinium, 2-[[3-[[3-[2-carboxy-1-(4-fluorophenyl)ethyl]-1H-indol-6-yl]oxy]propyl]amino]-1-(phenylmethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 724478-53-9
CMF C32 H31 F N3 O3



CM 2

CRN 14477-72-6
CMF C2 F3 O2



RN 724478-57-3 CAPLUS
CN 1,3-Dioxane-4,6-dione, 2,2-dimethyl-5-[2-[6-[3-(2-pyridinylamino)propoxy]-1H-indol-3-yl]-2-[4-(trifluoromethoxy)phenyl]ethyl]- (CA INDEX NAME)

Print selected from 10552348.trn



RN 724478-58-4 CAPLUS
CN 1,3-Dioxane-4,6-dione, 5-[2-(2,1,3-benzothiadiazol-5-yl)-2-[6-[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]propoxy]-1H-indol-3-yl]ethyl]-2,2-dimethyl- (CA INDEX NAME)



RN 724478-62-0 CAPLUS
CN 1H-Indole-3-propanoic acid, 6-[3-[(3-amino-2-pyridinyl)amino]propoxy]-β-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354823-39-5
CMF C25 H26 N4 O3



CM 2

Print selected from 10552348.trn

CRN 76-05-1
CMF C2 H F3 O2



L4 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
2004:269873 Document No. 140:297473 Methods for inhibition of angiogenesis using αvβ3 integrin antagonists. Brooks, Peter C.; Cheresh, David A. (The Scripps Research Institute, USA). U.S. Pat. Appl. Publ. US 20040063790 A1 20040401, 88 pp., Cont.-in-part of U.S. Pat. Appl. 2003 176,334. (English). CODEN: USXXCO. APPLICATION: US 2003-402212 20030328. PRIORITY: US 1996-18773P 19960531; US 1996-15869P 19960531; WO 1997-US9158 19970530; US 1999-194468 19990323; US 2002-115223 20020402.

AB The invention describes methods for inhibition angiogenesis in tissues using organic peptidomimetic αvβ3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in tumor tissues and metastases using therapeutic compns. containing αvβ3 antagonists. The antagonists are organic compds. having a basic group and an acidic group spaced from one another by a distance in the range of about 10 Angstroms to about 100 Angstroms, as described in detail herein.

IT 354822-33-6 354823-47-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods for inhibition of angiogenesis using αvβ3 integrin antagonists)

RN 354822-33-6 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-6-[3-(2-pyridinylamino)propoxy]- (CA INDEX NAME)



RN 354823-47-5 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-6-[3-(2-pyridinylamino)propoxy]-, (βS)- (CA INDEX NAME)

Absolute stereochemistry.

Print selected from 10552348.trn



L4 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
2003:656600 Document No. 139:191476 αvβ3 and/or αvβ5 integrin receptor antagonist for the treatment of eye diseases. Bender, Hans-Markus; Lang, Ulrich; Wiesner, Matthias; Friedlander, Martin (Merck Patent G.m.b.H., Germany). PCT Int. Appl. WO 2003068253 A1 20030821, 63 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-EP1369 20030212. PRIORITY: EP 2002-3432 20020214.

GI



AB Method and compns. for prophylaxis and/or treatment of diseases of the eye using antagonists of the integrin receptors αvβ3 and/or αvβ5 are described. The compns. can be nanoparticles and are administered to the eye by injection into the subTenon's space of the eye. An example compound is I.

IT 354822-33-6 354822-36-9
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(αvβ3 and/or αvβ5 integrin receptor antagonist for the treatment of eye diseases)

RN 354822-33-6 CAPLUS

CN 1H-Indole-3-propanoic acid, β-phenyl-6-[3-(2-pyridinylamino)propoxy]- (CA INDEX NAME)

Print selected from 10552348.trn



RN 354822-36-9 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-5-[3-(2-pyridinylamino)propoxy]- (CA INDEX NAME)



L4 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
2003:133028 Document No. 138:180760 Integrin inhibitors for the treatment of eye diseases. Bender, Hans Markus; Haunschild, Jutta; Lang, Ulrich; Wiesner, Matthias; Friedlander, Martin (Merck Patent GmbH, Germany). PCT Int. Appl. WO 2003013511 A1 20030220, 64 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-EP7377 20020703. PRIORITY: US 2001-308851P 20010801.

AB Methods and compns. for prophylaxis and/or treatment of diseases of the eye using antagonists of the integrin receptors αvβ3 and/or αvβ5 are disclosed. The compns. can be nanoparticles and are administered to the eye by injection into the vitreous body of the eye.

IT 354822-33-6 354822-36-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(integrin inhibitors for treatment of eye diseases)

RN 354822-33-6 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-6-[3-(2-pyridinylamino)propoxy]- (CA INDEX NAME)

Print selected from 10552348.trn



RN 354822-36-9 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-5-[3-(2-pyridinylamino)propoxy]- (CA INDEX NAME)



L4 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
2002:594672 Document No. 137:154848 Preparation of indoles and their use as αvβ3 and αvβ5 integrin antagonists. Lu, Tianbao; Lafrance, Louis Vincent; Markotan, Thomas P.; Marugan, Juan Jose; Marder, Victor J.; U'Prichard, David C.; Anaclerio, Beth M.; Guo, Zihong; Pan, Wenxi; Leonard, Kristi A. (3-Dimensional Pharmaceuticals, Inc., USA). PCT Int. Appl. WO 2002060438 A1 20020808, 228 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-US2366 20020129. PRIORITY: US 2001-264260P 20010129; US 2001-324519P 20010926.
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1-R5 = H, halo, alkyl, etc.; R6-R9 = H, alkyl, hydroxyalkyl, etc.; R10-R13 = H, OH, alkyl, etc.; R14 = H, or a functionality that acts as a prodrug; X = O, S, CH2, etc.; a, k, v = 0, 1; i, j, m, n = 0-4], their pharmaceutically acceptable salts, prodrugs and formulations were prepared For example, hydrogenation of acrylic ester II, prepared from 7-[2-[1-(2-Methoxycarbonyl-1-(pyridin-3-yl)vinyl)-1H-indol-5-yloxy]ethyl]-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-Bu ester and pyridin-3-ylpropynoic acid Me ester, followed by BOC deprotection, and ester hydrolysis provided claimed indole III. Indole

Print selected from 10552348.trn

III inhibited human αvβ3-vitronectin interaction at an IC50 of 0.24 nM, studies for an addnl. 6 examples are provided, ranging in values from 670 to 0.24 nM. Compds. I may be used in treatment of pathol. conditions mediated by αvβ3 and αvβ5 integrins, including such conditions as tumor growth, inflammation, rheumatoid arthritis, etc..

IT 445489-73-6P, 3-[5-[3-(2-Pyridylamino)propoxy]indolyl]propanoic acid ammonium salt
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(drug candidate; preparation of indoles and their use as αvβ3 and αvβ5 integrin antagonists)

RN 445489-73-6 CAPLUS

CN 1H-Indole-1-propanoic acid, 5-[3-(2-pyridinylamino)propoxy]-, ammonium salt (1:1) (CA INDEX NAME)



IT 402933-31-7P, 2-[5-[3-(2-Pyridylamino)propoxy]indolyl]acetic acid 445489-74-7P 445489-75-8P, 3-[2-Methyl-5-[3-(2-pyridylamino)propoxy]indolyl]propanoic acid sodium salt 445489-76-9P, 2-[trans-2-[5-[3-(2-Pyridylamino)propoxy]indolyl]cyclopropyl]acetic acid 445489-78-1P, 2-Benzyl-3-[5-[3-(2-pyridylamino)propoxy]indolyl]propanoic acid 445489-79-2P 445489-80-5P, 2-[[5-[3-(2-Pyridylamino)propoxy]indolyl]methyl]pentanoic acid 445489-81-6P, 2-[[5-[3-(2-Pyridylamino)propoxy]indolyl]methyl]octanoic acid 445490-29-9P, 3-[5-[3-(2-Pyridylamino)propoxy]indolyl]propanoic acid 445490-30-2P, 3-[2-Methyl-5-[3-(2-pyridylamino)propoxy]indolyl]propanoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of indoles and their use as αvβ3 and αvβ5 integrin antagonists)

RN 402933-31-7 CAPLUS

CN 1H-Indole-1-acetic acid, 5-[3-(2-pyridinylamino)propoxy]- (CA INDEX NAME)



Print selected from 10552348.trn

RN 445489-74-7 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[3-(2-pyridinylamino)propoxy]-, ammonium salt (1:1) (CA INDEX NAME)



RN 445489-75-8 CAPLUS
CN 1H-Indole-1-propanoic acid, 2-methyl-5-[3-(2-pyridinylamino)propoxy]-, sodium salt (1:1) (CA INDEX NAME)



RN 445489-76-9 CAPLUS
CN Cyclopropaneacetic acid, 2-[5-[3-(2-pyridinylamino)propoxy]-1H-indol-1-yl]-, (1R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 445489-78-1 CAPLUS
CN 1H-Indole-1-propanoic acid, α-(phenylmethyl)-5-[3-(2-pyridinylamino)propoxy]- (CA INDEX NAME)

Print selected from 10552348.trn



RN 445489-79-2 CAPLUS
CN 1H-Indole-1-propanoic acid, α-methyl-5-[3-(2-pyridinylamino)propoxy]- (CA INDEX NAME)



RN 445489-80-5 CAPLUS
CN 1H-Indole-1-propanoic acid, α-propyl-5-[3-(2-pyridinylamino)propoxy]- (CA INDEX NAME)



RN 445489-81-6 CAPLUS
CN 1H-Indole-1-propanoic acid, α-hexyl-5-[3-(2-pyridinylamino)propoxy]- (CA INDEX NAME)



RN 445490-29-9 CAPLUS
CN 1H-Indole-1-propanoic acid, 5-[3-(2-pyridinylamino)propoxy]- (CA INDEX NAME)

Print selected from 10552348.trn



RN 445490-30-2 CAPLUS
CN 1H-Indole-1-propanoic acid, 2-methyl-5-[3-(2-pyridinylamino)propoxy]- (CA INDEX NAME)



IT 445490-32-4P, Ethyl 3-[5-[3-(2-pyridylamino)propoxy]indolyl]propanoate 445490-35-7P, Methyl 2-[5-[3-(2-pyridylamino)propoxy]indolyl]acetate 445490-39-1P, Methyl 3-[2-methyl-5-[3-(2-pyridylamino)propoxy]indolyl]propanoate 445490-42-6P, Ethyl 2-[5-[3-(2-pyridylamino)propoxy]indolyl]cyclopropanecarboxylate 445490-51-7P, Methyl 2-methyl-3-[5-[3-(2-pyridylamino)propoxy]indolyl]propanoate 445490-54-0P, Methyl 2-[[5-[3-(2-pyridylamino)propoxy]indolyl]methyl]pentanoate 445490-57-3P, Methyl 2-[[5-[3-(2-pyridylamino)propoxy]indolyl]methyl]octanoate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of indoles and their use as αvβ3 and αvβ5 integrin antagonists)
RN 445490-32-4 CAPLUS
CN 1H-Indole-1-propanoic acid, 5-[3-(2-pyridinylamino)propoxy]-, ethyl ester (CA INDEX NAME)



RN 445490-35-7 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[3-(2-pyridinylamino)propoxy]-, methyl ester (CA INDEX NAME)

Print selected from 10552348.trn



RN 445490-39-1 CAPLUS
CN 1H-Indole-1-propanoic acid, 2-methyl-5-[3-(2-pyridinylamino)propoxy]-, methyl ester (CA INDEX NAME)



RN 445490-42-6 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[5-[3-(2-pyridinylamino)propoxy]-1H-indol-1-yl]-, ethyl ester (CA INDEX NAME)



RN 445490-51-7 CAPLUS
CN 1H-Indole-1-propanoic acid, α-methyl-5-[3-(2-pyridinylamino)propoxy]-, methyl ester (CA INDEX NAME)



RN 445490-54-0 CAPLUS
CN 1H-Indole-1-propanoic acid, α-propyl-5-[3-(2-pyridinylamino)propoxy]-, methyl ester (CA INDEX NAME)

Print selected from 10552348.trn



RN 445490-57-3 CAPLUS
CN 1H-Indole-1-propanoic acid, α-hexyl-5-[3-(2-pyridinylamino)propoxy]-, methyl ester (CA INDEX NAME)



L4 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
2002:293620 Document No. 136:309846 Preparation of substituted indoles as PPAR-γ binding agents. Stolle, Andreas; Dumas, Jacques P.; Carley, William; Coish, Phillip D. G.; Magnuson, Steven R.; Wang, Yamin; Nagarathnam, Dhanapalan; Lowe, Derek B.; Su, Ning; Bullock, William H.; Campbell, Ann-Marie; Qi, Ning; Baryza, Jeremy L.; Cook, James H. (Bayer Corporation, USA). PCT Int. Appl. WO 2002030895 A1 20020418, 233 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US42644 20011009. PRIORITY: US 2000-239195P 20001010; US 2000-243665P 20001027.
GI



I

AB The title compds. [I; R1 = R8R9; R8 = alkyl, alkenyl, alkynyl, etc.; R9 = (un)substituted Ph, cycloalkyl, heterocycloalkyl, etc.; X = (un)substituted NH, S, O; R2 = H, alkyl, halo, alkyl, etc.; R3 = R12R13;

R12 = alkyl, alkenyl, alkynyl, CO; R13 = (un)substituted cycloalkyl, cycloalkenyl, heterocycloalkyl, etc.; R4-R7 = H, OH, etc.], useful in treating or preventing PPAR-γ mediated diseases or conditions, such as osteopenia, osteoporosis, cancer, diabetes and atherosclerosis, were prepared Thus, hydrolysis of Et 3-(cyclopropylidenemethyl)-1-[3-(trifluoromethyl)benzyl]-1H-indole-2-carboxylate (preparation given) with NaOH in H2O/THF afforded 57% I [R1 = 3-F3CC6H4CH2; X = O; R2 = H; R3 = cyclopropylidenemethyl; R4-R7 = H] which showed IC50 of 100 pM and 9.99 nM against PPAR-γ binding.

IT 412004-73-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted indoles as PPAR-γ binding agents)

RN 412004-73-0 CAPLUS

CN 1H-Indole-2-carboxylic acid, 5-[3-(2-benzoxazolylmethylamino)propoxy]-3-(4-methoxyphenyl)-1-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)





IT 412007-19-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted indoles as PPAR-γ binding agents)

RN 412007-19-3 CAPLUS

CN 1H-Indole-2-carboxylic acid, 5-[3-(2-benzoxazolylmethylamino)propoxy]-3-(4-methoxyphenyl)-1-[[3-(trifluoromethyl)phenyl]methyl]-, ethyl ester (CA INDEX NAME)

Print selected from 10552348.trn



L4 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
2002:171893 Document No. 136:232323 Compounds containing a pyridinylaminopropoxybicyclic ring system useful as αvβ3 antagonists. Ish, Kumar Khanna; Yi, Yu; Balekudru, Devadas; Hwang-Fun, Lu; Nizal, S. Chandrakumar (Pharmacia Corporation, USA). PCT Int. Appl. WO 2002018377 A1 20020307, 125 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US26889 20010829. PRIORITY: US 2000-2000/PV228693 20000829.
GI



I

AB Title compds. were prepared for use as selective inhibitors or antagonists of the αvβ3 and/or αvβ5 integrin. Thus, the benzoxazepine I was prepared by treating 4-benzyloxysalicylaldehyde with BrCMe2CO2CH2Ph and H2NCH2CO2CMe3, debenzylating, cyclizing, reaction with 2-(3-hydroxypropylamino)pyridine 1-oxide, reduction of the N-oxide, and ester hydrolysis. The compds. showed activity in several vitronectin receptor assays.
IT 402933-31-7P 402933-32-8P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(compds. containing a pyridinylaminopropoxybicyclic ring system useful as αvβ3 antagonists)
RN 402933-31-7 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[3-(2-pyridinylamino)propoxy]- (CA INDEX NAME)

Print selected from 10552348.trn



RN 402933-32-8 CAPLUS
CN 1H-Indole-1-acetic acid, 5-[3-(2-pyridinylamino)propoxy]-, 2,2,2-trifluoroacetate (4:5) (CA INDEX NAME)

CM 1

CRN 402933-31-7
CMF C18 H19 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



L4 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
2001:597980 Document No. 135:180700 Preparation of indol-3-ylpropionates as integrin inhibitors.. Goodman, Simon; Gottschlich, Rudolf; Wiesner, Matthias (Merck Patent G.m.b.H., Germany). PCT Int. Appl. WO 2001058893 A2 20010816, 87 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (German). CODEN: PIXXD2. APPLICATION: WO 2001-EP84 20010105. PRIORITY: DE 2000-10006139 20000211.
GI

Print selected from 10552348.trn



I

AB Title compds. [I; A, B = O, S, NH, NR7, CO, CONH, bond; X = (substituted) alkylene; R1 = H, Z, (CH2)oAr; R2 = H, R7, COZ; R3 = NHR6, NR6C(:NR6)NHR6, Het; R4, R5 = H, O, R7, (CH2)oAr, OAr, etc.; R6 = H, COR7, COAr, R7, CO2R7, SO2R7, etc.; R7 = alkyl, cycloalkyl; Z = alkyl; Ar = (substituted) aryl; Het = (unsatd.) (substituted) mono- or bicyclic N-heterocyclyl; m = 0-6; n, o = 0-2], were prepared as integrin inhibitors useful for combating thrombosis, myocardial infarcts, coronary heart disease, arteriosclerosis, inflammation, tumors, osteoporosis, rheumatic arthritis, macular degenerative diseases, diabetic retinopathy, infections, restenosis after angioplasty, and pathol. conditions which are maintained or propagated by angiogenesis (no data). Thus, 6-benzyloxyindole, PhCHO, Meldrum's acid, and L-proline were stirred 3 h in MeCN to give 5-[phenyl-(6-O-benzylindol-3-yl)methyl]-2,2-dimethyl-1,3-dioxane-4,6-dione. The latter was refluxed with Cu powder in pyridine/EtOH to give Et 3-phenyl-3-(6-O-benzylindol-3-yl)propionate, which was hydrogenated in EtOH over Pd/C to give Et 3-phenyl-3-(6-hydroxyindol-3-yl)propionate. This was converted to 3-phenyl-3-[6-[3-(pyridin-2-ylamino)propoxy]indol-3-yl]propionic acid in several steps.

IT 354822-33-6P 354822-36-9P 354822-40-5P
354822-41-6P 354822-42-7P 354822-43-8P
354822-44-9P 354822-45-0P 354822-46-1P
354822-48-3P 354822-49-4P 354822-50-7P
354822-62-1P 354822-63-2P 354822-69-8P
354822-83-6P 354822-85-8P 354822-86-9P
354822-88-1P 354822-89-2P 354822-90-5P
354822-91-6P 354822-93-8P 354822-95-0P
354822-97-2P 354823-01-1P 354823-03-3P
354823-07-7P 354823-08-8P 354823-18-0P
354823-21-5P 354823-25-9P 354823-28-2P
354823-47-5P 354823-49-7P 354823-52-2P
354823-56-6P 354823-71-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indolylpropionates as integrin inhibitors)

RN 354822-33-6 CAPLUS

CN 1H-Indole-3-propanoic acid, β-phenyl-6-[3-(2-pyridinylamino)propoxy]- (CA INDEX NAME)

Print selected from 10552348.trn



RN 354822-36-9 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-5-[3-(2-pyridinylamino)propoxy]-
(CA INDEX NAME)



RN 354822-40-5 CAPLUS
CN 1H-Indole-3-propanoic acid, 6-[3-[(4,5-dihydro-1H-imidazol-2-
yl)amino]propoxy]-β-phenyl- (CA INDEX NAME)



RN 354822-41-6 CAPLUS
CN 1H-Indole-3-propanoic acid, β-(4-fluorophenyl)-6-[3-(2-
pyridinylamino)propoxy]- (CA INDEX NAME)



RN 354822-42-7 CAPLUS
CN 1H-Indole-3-propanoic acid, β-(3,5-dichlorophenyl)-6-[3-(2-
pyridinylamino)propoxy]- (CA INDEX NAME)

Print selected from 10552348.trn



RN 354822-43-8 CAPLUS
CN 1H-Indole-3-propanoic acid, β-[4-chloro-3-(trifluoromethyl)phenyl]-6-[3-(2-pyridinylamino)propoxy]- (CA INDEX NAME)



RN 354822-44-9 CAPLUS
CN 1H-Indole-3-propanoic acid, β-cyclohexyl-6-[3-(2-pyridinylamino)propoxy]- (CA INDEX NAME)



RN 354822-45-0 CAPLUS
CN 1H-Indole-3-propanoic acid, β-4-pyridinyl-6-[3-(2-pyridinylamino)propoxy]- (CA INDEX NAME)

Print selected from 10552348.trn



RN 354822-46-1 CAPLUS
CN 1H-Indole-3-propanoic acid, β-(3-chlorophenyl)-6-[3-(2-pyridinylamino)propoxy]- (CA INDEX NAME)



RN 354822-48-3 CAPLUS
CN 2,1,3-Benzothiadiazole-5-propanoic acid, β-[6-[3-(2-pyridinylamino)propoxy]-1H-indol-3-yl]- (CA INDEX NAME)



RN 354822-49-4 CAPLUS
CN 1H-Indole-3-propanoic acid, β-(3-hydroxyphenyl)-6-[3-[(3,4,5,6-tetrahydro-2-pyridinyl)amino]propoxy]- (CA INDEX NAME)



RN 354822-50-7 CAPLUS
CN 1H-Indole-3-propanoic acid, β-[4-(methoxycarbonyl)phenyl]-6-[3-(2-pyridinylamino)propoxy]- (CA INDEX NAME)

Print selected from 10552348.trn



RN 354822-62-1 CAPLUS
CN 1H-Indole-3-propanoic acid, β-(3-chlorophenyl)-6-[3-(2-pyridinylamino)propoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354822-46-1
CMF C25 H24 Cl N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 354822-63-2 CAPLUS
CN 1H-Indole-3-propanoic acid, β-4-pyridinyl-6-[3-(2-pyridinylamino)propoxy]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 354822-45-0
CMF C24 H24 N4 O3



Print selected from 10552348.trn

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 354822-69-8 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-5-[3-(2-pyridinylamino)propoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354822-36-9
CMF C25 H25 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 354822-83-6 CAPLUS
CN 1H-Indole-3-propanoic acid, β-(4-fluorophenyl)-6-[3-(2-pyridinylamino)propoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354822-41-6
CMF C25 H24 F N3 O3

Print selected from 10552348.trn



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 354822-85-8 CAPLUS
CN 1H-Indole-3-propanoic acid, β-[3,5-bis(trifluoromethyl)phenyl]-6-[3-(2-pyridinylamino)propoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354822-84-7
CMF C27 H23 F6 N3 O3





CM 2

CRN 76-05-1
CMF C2 H F3 O2

Print selected from 10552348.trn



RN 354822-86-9 CAPLUS
CN 1H-Indole-3-propanoic acid, β-(3,5-dichlorophenyl)-6-[3-(2-pyridinylamino)propoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354822-42-7
CMF C25 H23 Cl2 N3 O3





CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 354822-88-1 CAPLUS
CN 1H-Indole-3-propanoic acid, β-(2,4-dichlorophenyl)-6-[3-(2-pyridinylamino)propoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354822-87-0
CMF C25 H23 Cl2 N3 O3

Print selected from 10552348.trn



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 354822-89-2 CAPLUS
CN 1H-Indole-3-propanoic acid, β-[4-chloro-3-(trifluoromethyl)phenyl]-6-[3-(2-pyridinylamino)propoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354822-43-8
CMF C26 H23 Cl F3 N3 O3





CM 2

CRN 76-05-1
CMF C2 H F3 O2

Print selected from 10552348.trn



RN 354822-90-5 CAPLUS
CN 1H-Indole-3-propanoic acid, β-cyclohexyl-6-[3-(2-pyridinylamino)propoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354822-44-9
CMF C25 H31 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 354822-91-6 CAPLUS
CN 2,1,3-Benzothiadiazole-5-propanoic acid, β-[6-[3-(2-pyridinylamino)propoxy]-1H-indol-3-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 354822-48-3
CMF C25 H23 N5 O3 S



Print selected from 10552348.trn

CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 354822-93-8 CAPLUS
CN 1H-Indole-3-propanoic acid, β-(2,6-difluorophenyl)-6-[3-(2-pyridinylamino)propoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354822-92-7
CMF C25 H23 F2 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 354822-95-0 CAPLUS
CN 1H-Indole-3-propanoic acid, β-(2-chloro-3,6-difluorophenyl)-6-[3-(2-pyridinylamino)propoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354822-94-9

Print selected from 10552348.trn

CMF C25 H22 Cl F2 N3 O3





CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 354822-97-2 CAPLUS
CN 1H-Indole-3-propanoic acid, 6-[3-(2-pyridinylamino)propoxy]-β-(2,4,6-trifluorophenyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354822-96-1
CMF C25 H22 F3 N3 O3



CM 2

Print selected from 10552348.trn

CRN 76-05-1
CMF C2 H F3 O2



RN 354823-01-1 CAPLUS
CN 1H-Indole-3-propanoic acid, 6-[3-(2-pyridinylamino)propoxy]-β-[4-(trifluoromethoxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354823-00-0
CMF C26 H24 F3 N3 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 354823-03-3 CAPLUS
CN 1H-Indole-3-propanoic acid, 6-[3-(2-pyridinylamino)propoxy]-β-[3-(trifluoromethoxy)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354823-02-2
CMF C26 H24 F3 N3 O4

Print selected from 10552348.trn



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 354823-07-7 CAPLUS
CN 2,1,3-Benzothiadiazole-5-propanoic acid, β-[6-[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]propoxy]-1H-indol-3-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 354823-06-6
CMF C23 H24 N6 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



Print selected from 10552348.trn

RN 354823-08-8 CAPLUS
CN 1H-Indole-3-propanoic acid, 6-[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]propoxy]-β-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354822-40-5
CMF C23 H26 N4 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 354823-18-0 CAPLUS
CN 1H-Indole-3-propanoic acid, 6-[3-[(4,5-dihydro-5-oxo-1H-imidazol-2-yl)amino]propoxy]-β-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354823-17-9
CMF C23 H24 N4 O4



CM 2

Print selected from 10552348.trn

CRN 76-05-1
CMF C2 H F3 O2



RN 354823-21-5 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-6-[3-(2-pyrimidinylamino)propoxy]- (CA INDEX NAME)



RN 354823-25-9 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-6-[3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propoxy]- (CA INDEX NAME)



RN 354823-28-2 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-6-[3-[(3,4,5,6-tetrahydro-2-pyridinyl)amino]propoxy]- (CA INDEX NAME)



Print selected from 10552348.trn

RN 354823-47-5 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-6-[3-(2-pyridinylamino)propoxy]-, (βS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 354823-49-7 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-6-[3-(2-pyridinylamino)propoxy]-, hydrochloride (1:1), (βS)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 354823-52-2 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-6-[3-(2-pyridinylamino)propoxy]-, (βS)-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 354823-47-5
CMF C25 H25 N3 O3

Absolute stereochemistry.



Print selected from 10552348.trn

CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 354823-56-6 CAPLUS
CN 1H-Indole-3-propanoic acid, 6-[3-(1H-imidazol-2-ylamino)propoxy]-β-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354823-55-5
CMF C23 H24 N4 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 354823-71-5 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-6-[3-(2-pyridinylamino)propoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354822-33-6
CMF C25 H25 N3 O3

Print selected from 10552348.trn



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 354823-46-4P
RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indolylpropionates as integrin inhibitors)
RN 354823-46-4 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-6-[3-(2-pyridinylamino)propoxy]-, ethyl ester, (βS)- (CA INDEX NAME)

Absolute stereochemistry.



IT 354822-55-2P 354822-57-4P 354822-59-6P
354822-61-0P 354822-98-3P 354822-99-4P
354823-04-4P 354823-05-5P 354823-20-4P
354823-23-7P 354823-26-0P 354823-38-4P
354823-40-8P 354823-43-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indolylpropionates as integrin inhibitors)
RN 354822-55-2 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-6-[3-[2-pyridinyl[(2,2,2-

trichloroethoxy)carbonyl]amino]propoxy]-, ethyl ester (CA INDEX NAME)



RN 354822-57-4 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-6-[3-(2-pyridinylamino)propoxy]-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 354822-56-3
CMF C27 H29 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 354822-59-6 CAPLUS
CN 1H-Indole-3-propanoic acid, 6-[3-[1H-imidazol-2-yl[(2,2,2-trichloroethoxy)carbonyl]amino]propoxy]-β-phenyl-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

Print selected from 10552348.trn

CRN 354822-58-5
CMF C28 H29 Cl3 N4 O5



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 354822-61-0 CAPLUS
CN 1H-Indole-3-propanoic acid, 6-[3-(1H-imidazol-2-ylamino)propoxy]-β-phenyl-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 354822-60-9
CMF C25 H28 N4 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2

Print selected from 10552348.trn



RN 354822-98-3 CAPLUS
CN 2-Pyridinamine, N-[3-(1H-indol-6-yloxy)propyl]- (CA INDEX NAME)



RN 354822-99-4 CAPLUS
CN 1,3-Dioxane-4,6-dione, 2,2-dimethyl-5-[[6-[3-(2-pyridinylamino)propoxy]-1H-indol-3-yl][4-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)



RN 354823-04-4 CAPLUS
CN 1H-Imidazol-2-amine, 4,5-dihydro-N-[3-(1H-indol-6-yloxy)propyl]- (CA INDEX NAME)



RN 354823-05-5 CAPLUS
CN 1,3-Dioxane-4,6-dione, 5-[2,1,3-benzothiadiazol-5-yl[6-[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]propoxy]-1H-indol-3-yl]methyl]-2,2-dimethyl- (CA INDEX NAME)

Print selected from 10552348.trn



RN 354823-20-4 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-6-[3-(2-pyrimidinylamino)propoxy]-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 354823-19-1
CMF C26 H28 N4 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 354823-23-7 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-6-[3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]propoxy]-, ethyl ester (CA INDEX NAME)

Print selected from 10552348.trn



RN 354823-26-0 CAPLUS
CN 1H-Indole-3-propanoic acid, β-phenyl-6-[3-[(3,4,5,6-tetrahydro-2-pyridinyl)amino]propoxy]-, ethyl ester (CA INDEX NAME)



RN 354823-38-4 CAPLUS
CN 1H-Indole-3-propanoic acid, 6-[3-[(3-nitro-2-pyridinyl)amino]propoxy]-β-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354823-37-3
CMF C25 H24 N4 O5



CM 2

CRN 76-05-1
CMF C2 H F3 O2

Print selected from 10552348.trn



RN 354823-40-8 CAPLUS
CN 1H-Indole-3-propanoic acid, 6-[3-[(3-amino-2-pyridinyl)amino]propoxy]-β-phenyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 354823-39-5
CMF C25 H26 N4 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 354823-43-1 CAPLUS
CN 1H-Indole-3-propanoic acid, 6-[3-[[3-(acetylamino)-2-pyridinyl]amino]propoxy]-β-phenyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 354823-42-0
CMF C27 H28 N4 O4

Print selected from 10552348.trn



CM 2

CRN 76-05-1
CMF C2 H F3 O2



=>
Connection closed by remote host

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTADKO1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 3	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 4	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 5	APR 28	IMSRESEARCH reloaded with enhancements
NEWS 6	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS 7	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 8	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 9	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 10	JUN 13	USPATFULL and USPAT2 updated with 11-character

Print selected from 10552348.trn

```
                  patent numbers for U.S. applications
 NEWS 11  JUN 19  CAS REGISTRY includes selected substances from
                  web-based collections
 NEWS 12  JUN 25  CA/CAplus and USPAT databases updated with IPC
                  reclassification data
 NEWS 13  JUN 30  AEROSPACE enhanced with more than 1 million U.S.
                  patent records
 NEWS 14  JUN 30  EMBASE, EMBAL, and LEMBASE updated with additional
                  options to display authors and affiliated
                  organizations
 NEWS 15  JUN 30  STN on the Web enhanced with new STN AnaVist
                  Assistant and BLAST plug-in
 NEWS 16  JUN 30  STN AnaVist enhanced with database content from EPFULL
 NEWS 17  JUL 28  CA/CAplus patent coverage enhanced
 NEWS 18  JUL 28  EPFULL enhanced with additional legal status
                  information from the epoline Register
 NEWS 19  JUL 28  IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
 NEWS 20  JUL 28  STN Viewer performance improved
 NEWS 21  AUG 01  INPADOCDB and INPAFAMDB coverage enhanced
 NEWS 22  AUG 13  CA/CAplus enhanced with printed Chemical Abstracts
                  page images from 1967-1998
 NEWS 23  AUG 15  CAOLD to be discontinued on December 31, 2008
 NEWS 24  AUG 15  CAplus currency for Korean patents enhanced
 NEWS 25  AUG 25  CA/CAplus, CASREACT, and IFI and USPAT databases
                  enhanced for more flexible patent number searching
 NEWS 26  AUG 27  CAS definition of basic patents expanded to ensure
                  comprehensive access to substance and sequence
                  information

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:09:05 ON 08 SEP 2008

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.
```

Print selected from 10552348.trn

=> FILE REGISTRY

FILE 'REGISTRY' ENTERED AT 14:10:00 ON 08 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 7 SEP 2008 HIGHEST RN 1047406-12-1
DICTIONARY FILE UPDATES: 7 SEP 2008 HIGHEST RN 1047406-12-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10552358-12.str



chain nodes :
10 11 12 13 14 21 22
ring nodes :
1 2 3 4 5 6 7 8 9 25 26 27 28 29 30
ring/chain nodes :
15 16 17 18 19 20 23 24
chain bonds :
3-10 7-21 10-11 11-12 11-15 11-16 12-13 12-17 12-18 13-14 13-19 13-20
14-27 21-22 22-23 22-24
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 25-26 25-30 26-27 27-28 28-29
29-30
exact/norm bonds :
3-10 5-7 6-9 7-8 8-9 10-11 13-14 14-27 22-23 22-24
exact bonds :
7-21 11-12 11-15 11-16 12-13 12-17 12-18 13-19 13-20 21-22

Print selected from 10552348.trn

normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 25-26 25-30 26-27 27-28 28-29 29-30

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom
 30:Atom

L1   STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1   STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 14:10:15 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   30 TO ITERATE

100.0% PROCESSED   30 ITERATIONS   0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 272 TO   928
PROJECTED ANSWERS: 0 TO   0

L2   0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 14:10:21 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   717 TO ITERATE

100.0% PROCESSED   717 ITERATIONS   0 ANSWERS

Print selected from 10552348.trn

SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1